HD-OPM Archive
Topics › Lp(a)

Novartis Lp(a)HORIZON: pelacarsen failed to reduce heart attacks and strokes

Louis Nervegna · Sep 04, 2026 · ♥ 20 reactions · 24 comments · original Facebook post
Lp(a)PCSK9, ezetimibe & newer drugs
AI summary & key facts

Louis shares the first outcome-trial result for an Lp(a)-lowering drug: topline data from Novartis say pelacarsen lowered Lp(a) but did not show reduced cardiovascular risk overall. He says the result seriously questions whether Lp(a) is directly causal, noting only a press announcement is available so far.

The first randomized outcome trial to test Lp(a) lowering drugs has failed to show any benefit at reducing heart attacks and strokes (MACE).

We only have a topline press announcement from Novartis at this point, but nevertheless, this result is going to seriously call into question the assumption that Lp(a) is directly causal in heart disease.

NovartisNovartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)novartis.com

Quoted from the press release:

“Although lower Lp(a) levels were observed with pelacarsen, the findings did not demonstrate that this translated into reduced cardiovascular risk in the overall study population. These are not the results we hoped for, but they provide important evidence that advances scientific understanding of the relationship between Lp(a) lowering and cardiovascular outcomes and may help inform future approaches to cardiovascular risk management.”

#lpaHD #novartisHD #lpasummaryHD #pelacarsenHD #horizonHD

Research cited

Shared from Joel Kahn · original post

BREAKING NEWS. The first drug for Lp(a) is a failure. Shocking. Novartis announced the results today. Disappointing

← newer: BMJ review: calcium and vitamin D supplements offer little bolder: Conspiracy believers overrate their abilities and overestima →